Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Biotechnology company in the Healthcare sector, currently trading at $46.92. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of KNSA = $61.87 (+31.9% from the current price, the stock appears undervalued). Analyst consensus target is KNSA = $56 (+18.6% upside).
Valuation: KNSA trades at a trailing Price-to-Earnings (P/E) of 58 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.79.
Financials: revenue is $678M, +46.5%/yr average growth. Net income is $59M, growing at -87.5%/yr. Net profit margin is 8.7% (thin). Gross margin is 54.6% (-24.1 pp trend).
Balance sheet: total debt is $9M against $568M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 3.79 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $764M.
Analyst outlook: 10 / 10 analysts rate KNSA as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 58/100 (Partial), Past 75/100 (Partial), Health 100/100 (Pass), Moat 55/100 (Partial), Future 94/100 (Pass), Income 45/100 (Partial).
